ALT
Altimmune, Inc.
Next earnings Aug 10, 2026 (before open) · consensus $-0.16 EPS, $1.77K rev
Last earnings -1.9% on 2026-05-13
$2.82
▼ -1.74%$2.82▼ -59.66%
over 1Y
L $2.59EODHDH $7.71
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-1.7%
1W-3.8%
1M-5.4%
3M-6.6%
YTD-19.7%
1Y-59.7%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 15 analysts
Buy
Revenue grew 105.0% YoY; but unprofitable (net margin -214861.0%).
Revenue (FY2025) $41.0K · FY2025
Altimmune, Inc. shows $41.0K in FY2025 revenue (+105.0% YoY), a -214861.0% net margin, and -39.2% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $4.41M | -$68.0K | $426K | $20.0K | $41.0K |
| Gross profit | — | — | — | — | — |
| Operating income | -$96.9M | -$87.7M | -$95.9M | -$103M | -$94.5M |
| Net income | -$97.1M | -$84.7M | -$88.4M | -$95.1M | -$88.1M |
| Diluted EPS | -$2.35 | -$1.81 | -$1.66 | -$1.34 | -$1.00 |
| Net margin | -2201.6% | 124577.9% | -20762.2% | -475295.0% | -214861.0% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$357M
EV / EBITDA—
EV / Sales8715.2
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-24.0%
FCF yield-18.4%
Quality & risk
ROIC (est.)-28.8%
Free cash flow-$67.5M
Total debt$34.3M
Net cash$9.47M
Altman Z-Score0.77 distress
Piotroski F-Score4/8
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+68.9%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRoutine disclosure cadence — no material red flags in recent filings.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-162026-06-16open ↗SCHEDULE 13G/AFiling2026-05-15open ↗S-8Filing2026-05-13open ↗10-QPeriod ending 2026-03-312026-05-13open ↗8-KPeriod ending 2026-05-132026-05-13open ↗SCHEDULE 13GFiling2026-05-12open ↗SCHEDULE 13GFiling2026-05-01open ↗SCHEDULE 13GFiling2026-05-01open ↗4Period ending 2026-05-012026-05-01open ↗4Period ending 2026-05-012026-05-01open ↗4Period ending 2026-05-012026-05-01open ↗4Period ending 2026-05-012026-05-01open ↗
Frequently asked
- Is Altimmune, Inc. (ALT) a buy?
- ALT currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 105.0% YoY; but unprofitable (net margin -214861.0%).
- What is Altimmune, Inc.'s quality score?
- ALT scores 46.17647058823529/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001326190, latest 10-Q filed 2026-05-13) · EODHD · as of 6/26/2026, 5:58:56 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.